Omega3for Dogs Calculator

EPA (eicosapentaenoic acid, 20:5n-3) and DHA (docosahexaenoic acid, 22:6n-3) are long-chain omega-3 fatty acids that compete with arachidonic acid, an omega-6, for the cyclooxygenase and lipoxygenase enzymes. Eicosanoids built from EPA are markedly less inflammatory than the series-2 prostaglandins and series-4 leukotrienes built from arachidonic acid, which is the mechanistic basis for using marine oil in canine osteoarthritis, atopic skin disease, chronic kidney disease, and cardiac cachexia. Dogs can elongate and desaturate plant-derived alpha-linolenic acid into EPA and DHA, but the conversion runs at only a few percent, so flaxseed is a poor substitute for fish oil. DHA has a separate structural role in retinal and neural membranes and is dosed for puppy development rather than for anti-inflammatory effect. Dosing scales with body weight and rises with therapeutic intent, from roughly 20 to 30 mg/kg of combined EPA and DHA for general maintenance up to 50 to 100 mg/kg for joint disease. Capsule counts follow from label content rather than capsule size: a typical 1000 mg fish oil softgel supplies only about 180 mg EPA and 120 mg DHA, so a 30 kg arthritic dog can require eight or more capsules daily, which is why pumps and concentrated liquids are usually more practical. Constraints include calories, since oil carries about 9 kcal per gram; dose-dependent diarrhea and greasy stool; prolonged bleeding time at high intakes, relevant before surgery; oxidative rancidity in poorly stored oil; and vitamin A toxicity if cod liver oil is used as the source. Published safe upper limits are usually expressed against metabolic body weight rather than raw kilograms.

Interest in marine omega-3 fatty acids began with epidemiology rather than veterinary medicine. During the 1970s the Danish researchers Hans Olaf Bang and Jorn Dyerberg studied Greenland Inuit populations whose diets were heavy in seal and fish, reporting low rates of ischaemic heart disease alongside distinctive plasma fatty acid profiles and drawing attention to EPA. Over the following two decades the eicosanoid pathways were worked out in detail, and the proposition that dietary fat composition could shift an animal's inflammatory tone moved from hypothesis to accepted physiology. Companion-animal application came later and was driven by osteoarthritis. Therapeutic diets enriched with fish oil appeared in the 2000s, and a set of clinical trials published around 2010, including multicentre work led by James Roush at Kansas State University in the Journal of the American Veterinary Medical Association, reported improved weight bearing and lower owner-scored lameness in dogs fed high omega-3 diets. Nutrition of growing animals evolved in parallel: evidence that DHA supports retinal function and trainability in puppies led the Association of American Feed Control Officials to add a minimum combined EPA and DHA level to its growth and reproduction nutrient profile for dogs. Fish oil remains one of the few canine supplements supported by dose-response data generated in dogs rather than extrapolated from human trials.